Table 1.

Distribution of baseline demographics by treatment group

Demographic	IGF-1	Placebo	Significance (p)
Gender, men/women	110/57	100/63	0.424
Mean age, y	53.9	54.8	0.464
Bulbar/nonbulbar onset	34/133	34/129	0.917
Riluzole use, yes/no	116/51	113/50	0.979
Mean ALSFRS	38.7	38.7	0.976
Mean BDI score	6.7	6.6	0.690
Mean MMT score	7.0	6.9	0.566
Ethnicity
Caucasian	158	155
Hispanic	4	4
African American	3	3
Native American	1	0
Asian	1	0
Other	0	1

IGF-1 = insulin-like growth factor type I; ALSFRS = ALS functional rating scale; BDI = Beck Depression Inventory; MMT = manual muscle testing.